Table 2.
Baseline characteristics based on Day 100 ALC/AMC.
| Characteristics | Day 100 ALC/AMC ≥ 1.3 (N = 99) |
Day 100 ALC/AMC < 1.3 (N = 32) |
P value |
|---|---|---|---|
| At diagnosis | |||
| Age, years, median (range) | 33 (18–68) | 32 (18–56) | 0.8 |
| Gender | <0.008 | ||
| Male | 44 (44%) | 23 (72%) | |
| Female | 55 (56%) | 9 (28%) | |
| Albumin (g/dL) | 4 (2–4.6) | 3.9 (2.2–4.6) | <0.008 |
| ALC × 109/L | 1.7 (0.2–2.9) | 0.5 (0.2–2.7) | <0.0001 |
| Hemoglobin (g/dL) | 12.6 (7.7–16.2) | 11.1 (8.1–15.4) | 0.07 |
| Mediastinal disease | <0.004 | ||
| ≥10 cm | 10 (10%) | 4 (34%) | |
| <10 cm | 89 (90%) | 21 (66%) | |
| Stage | 0.9 | ||
| I | 5 (5%) | 1 (3%) | |
| II | 42 (43%) | 14 (44%) | |
| III | 26 (26%) | 9 (28%) | |
| IV | 26 (26%) | 8 (25%) | |
| Stage | 0.9 | ||
| Limited | 46 (47%) | 15 (47%) | |
| Advanced | 52 (53%) | 17 (53%) | |
| WBC × 109/L | 8.0 (1.4–22.2) | 12.1 (2.3–20.1) | <0.0003 |
| IPS risk factors | |||
| Age, years | 0.9 | ||
| ≤45 | 82 (83%) | 27 (84%) | |
| >45 | 17 (17%) | 5 (16%) | |
| Albumin (g/dL) (N = 127) |
<0.002 | ||
| ≥4 | 68 (71%) | 12 (39%) | |
| <4 | 28 (29%) | 19 (61%) | |
| ALC × 109/L | <0.0001 | ||
| ≥0.6 | 92 (93%) | 14 (44%) | |
| <0.6 | 7 (7%) | 18 (56%) | |
| Hemoglobin (g/dL) | 0.06 | ||
| >10.5 | 81 (82%) | 21 (66%) | |
| ≤10.5 | 18 (18%) | 11 (34%) | |
| Male | 44 (44%) | 23 (72%) | <0.008 |
| Stage 4 | 26 (26%) | 8 (25%) | 0.9 |
| WBC × 109/L | <0.001 | ||
| >15 | 9 (9%) | 11 (34%) | |
| ≤15 | 90 (91%) | 21 (66%) | |
| IPS score | <0.01 | ||
| 0 | 26 (26%) | 4 (13%) | |
| 1 | 33 (34%) | 8 (25%) | |
| 2 | 21 (21%) | 6 (18%) | |
| 3 | 10 (10%) | 3 (9%) | |
| 4 | 6 (6%) | 4 (13%) | |
| 5 | 3 (3%) | 4 (13%) | |
| 6 | 0 (0%) | 3 (9%) | |
| IPS index | <0.009 | ||
| ≥3 | 19 (19%) | 14 (44%) | |
| <3 | 80 (81%) | 18 (56%) | |
| At transplant | |||
| Infused CD34+ stem cells × 106/kg | 5.3 (2.6–15.8) | 4.5 (2.1–13.2) | 0.1 |
| Pretransplant response | 0.06 | ||
| CR | 27 (27%) | 3 (9%) | |
| PR | 72 (72%) | 29 (91%) | |
| ALC × 109/L | 0.78 (0.1–3.67) | 0.39 (0.18–3.19) | <0.0001 |
| ALC × 109/L | <0.0001 | ||
| ≥0.5 | 80 (81%) | 10 (31%) | |
| <0.5 | 19 (19%) | 22 (69%) | |
| At day 100 post-APBHSCT | |||
| Age, years | 36 (18–66) | 34.5 (19–58) | 0.9 |
| Hemoglobin (g/dL) | 12.1 (8.5–16.7) | 11.4 (7.3–14.1) | 0.4 |
| WBC × 109/L | 4.6 (2.2–9.4) | 3.7 (1.5–14.3) | 0.1 |
| ANC × 109/L | 2.6 (0.8–6.9) | 2.4 (1.0–10.0) | 0.9 |
| ALC × 109/L | 1.33 (0.51–4.61) | 0.39 (0.15–3.94) | <0.0001 |
| AMC × 109/L | 0.43 (0.15–1.58) | 0.63 (0.29–4.02) | <0.0001 |
| Plts × 109/L | 172 (121–373) | 163 (177–334) | 0.2 |
Abbreviations: ALC: absolute lymphocyte count; ANC: absolute neutrophil count; AMC: absolute monocyte count; CR: complete remission; IPS: international prognostic score; PR: partial response; Plts: platelets; and WBC: white blood cell count.